Dimethylamine

Dimethylamine

SCHEMBL3255104

CNC.O=S(=O)(Cl)c1ccc(-c2ccccc2)s1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
EDNRB P24530 1/20 0.45
EDNRA P25101 1/20 0.45
CYP1A2 P05177 1/20 0.42
MAPK1 P28482 1/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
HDAC1 Q13547 1/20 0.41
ADAMTS5 Q9UNA0 5/20 0.41
MMP1 P03956 3/20 0.41
MMP14 P50281 1/20 0.41
ADAM17 P78536 1/20 0.41
PFKFB3 Q16875 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7341689 0.93 CA12 (0.44) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL957340 0.93 CA12 (0.44) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL7056144 0.89 MEN1 (0.49) RAB9AALDH1A1EDNRBEDNRAHDAC1
SCHEMBL6970542 0.80 HSD17B1 (0.45) EDNRBEDNRAPFKFB3CA12CA1
SCHEMBL7336143 0.80 HSD17B1 (0.45) EDNRBEDNRAPFKFB3CA12CA1
SCHEMBL7055469 0.79 CA1 (0.41) MMP1CA12CA1CA2CA9
SCHEMBL7549393 0.79 MMP2 (0.42) NPC1HPGDEDNRBEDNRAMMP1
SCHEMBL3254332 0.79 MMP2 (0.42) NPC1HPGDEDNRBEDNRAMMP1
SCHEMBL13357723 0.78 EDNRB (0.46) RAB9ANPC1KDM4EALDH1A1HPGD
SCHEMBL7053171 0.77 HSD17B1 (0.53) KDM4EPFKFB3CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373262-B1 AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS NOVARTIS AG (CH) 2010-05-12 EP disclosed
US-20070060569-A1 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors NOVARTIS AG (CH) 2007-03-15 US disclosed
US-20040235896-A1 Certain azacycloalkyl substituted acetic acid derivatives FUJIMOTO ROGER AKI (US) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060569-A1 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors MMP9, MMP1, MMP13 RAB9A 1513/4885NPC1 2131/4885KDM4E 1602/4885
US-20040235896-A1 Certain azacycloalkyl substituted acetic acid derivatives MMP1, MMP9, MMP13 RAB9A 1715/4885NPC1 1567/4885KDM4E 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.